Chidamide plus hormone therapy after chemotherapy for breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies chidamide added to standard hormone (endocrine) therapy to help prevent breast cancer from coming back after initial chemotherapy. It may help by keeping cancer under control for longer in people with HR-positive, HER2-negative breast cancer who respond to first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman, age 18 to 70, and you are postmenopausal or premenopausal.
- Your breast cancer is HR-positive and HER2-negative (HER2 negative is defined by specific lab test results).
- You have locally advanced, recurring, or metastatic breast cancer that has been treated with local therapy and/or chemotherapy.
- After 4 to 8 cycles of first chemotherapy, your cancer is responding (better) or stable, and you are entering maintenance treatment.
- You have at least one measurable tumor spot on scans and your performance status (ECOG) is 0 to 2.
- Your blood counts, liver, and kidney function meet required safety limits, and any chemotherapy side effects are mostly resolved (NCI toxicity level 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
This trial tests a combination of a CDK4/6 inhibitor (a type of targeted therapy) with hormone therapy given before surgery for early-stage breast cancer that is hormone receptor-positive and HER2-negative. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of two drugs (dalpiciclib and an HDAC inhibitor) for people with hormone receptor-positive, HER2-negative advanced breast cancer that has progressed after a CDK4/6 inhibitor. The goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs (chidamide, an angiogenesis inhibitor, and fulvestrant) for advanced hormone-positive, HER2-negative breast cancer that has worsened after CDK4/6 inhibitor treatment. The goal is to see if this combination can slow cancer growth for a longer time.
This trial tests a combination of three drugs (chidamide, a PD-1 inhibitor, and anlotinib) to see if they can shrink or slow the growth of advanced breast cancer that is HER2-low and hormone receptor positive, and has stopped responding to endocrine therapy.
Hear when a new HR-positive, HER2-negative Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.